We found that the combinational treatment enhances a reduction in BCL2 mRNA expression levels, providing an alternative approach for BCL-2 inhibition in CLL that could have therapeutic implications for the treatment of refractory CLL cases. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.